Safety and Immunogenicity of Inactivated Poliovirus Vaccine Made From Sabin Strains: A Phase II, Randomized, Positive-Controlled Trial
Background. The production of Sabin inactivated polio virus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine (OPV) era. We conducted a phase II, randomized, positive-controlled trial to assess the safety and immunogenicity of Sabin IPV. Methods. The...
Saved in:
| Published in | The Journal of infectious diseases Vol. 205; no. 2; pp. 237 - 243 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford
Oxford University Press
15.01.2012
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0022-1899 1537-6613 1537-6613 |
| DOI | 10.1093/infdis/jir723 |
Cover
| Abstract | Background. The production of Sabin inactivated polio virus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine (OPV) era. We conducted a phase II, randomized, positive-controlled trial to assess the safety and immunogenicity of Sabin IPV. Methods. The test groups (A, B, and C) received 3 doses of high, middle, and low D antigen (D Ag) of Sabin IPV at ages 2, 3, and 4 months, respectively. Infants in 2 control groups, group D and group E, received 3 doses of trivalent OPV and conventional IPV (cIPV), respectively, on the same schedule as that of groups A, B, and C. Serum samples were collected before and 30 days after the administration of the third dose. Results. In total, 500 infants were randomly assigned to 5 groups, and 449 infants completed the vaccine series. No serious adverse events were associated with vaccinations. After 3 doses, the seroconversion rates in groups A, B, C, D, and E were 100%, 97.8%, 96.6%, 100%, and 90.1%, respectively, for type 1 poliovirus; 97.7%, 95.7%, 78.7%, 100%, and 90.1%, respectively, for type 2; and 98.8%, 98.9%, 93.3%, 100%, and 97.8%, respectively, for type 3. Conclusions. Sabin IPV has good safety characteristics. The seroconversion rates for type 1 poliovirus (most appropriate concentration, 15 D Ag units [DU]), type 2 (32 DU), and type 3 (45 DU) Sabin IPV were similar to those of the OPV and cIPV control groups. Clinical Trials Registration. NCT01056705. |
|---|---|
| AbstractList | The production of Sabin inactivated poliovirus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine (OPV) era. We conducted a phase II, randomized, positive-controlled trial to assess the safety and immunogenicity of Sabin IPV.
The test groups (A, B, and C) received 3 doses of high, middle, and low D antigen (D Ag) of Sabin IPV at ages 2, 3, and 4 months, respectively. Infants in 2 control groups, group D and group E, received 3 doses of trivalent OPV and conventional IPV (cIPV), respectively, on the same schedule as that of groups A, B, and C. Serum samples were collected before and 30 days after the administration of the third dose.
In total, 500 infants were randomly assigned to 5 groups, and 449 infants completed the vaccine series. No serious adverse events were associated with vaccinations. After 3 doses, the seroconversion rates in groups A, B, C, D, and E were 100%, 97.8%, 96.6%, 100%, and 90.1%, respectively, for type 1 poliovirus; 97.7%, 95.7%, 78.7%, 100%, and 90.1%, respectively, for type 2; and 98.8%, 98.9%, 93.3%, 100%, and 97.8%, respectively, for type 3.
Sabin IPV has good safety characteristics. The seroconversion rates for type 1 poliovirus (most appropriate concentration, 15 D Ag units [DU]), type 2 (32 DU), and type 3 (45 DU) Sabin IPV were similar to those of the OPV and cIPV control groups.
NCT01056705. Background. The production of Sabin inactivated polio virus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine (OPV) era. We conducted a phase II, randomized, positive-controlled trial to assess the safety and immunogenicity of Sabin IPV. Methods. The test groups (A, B, and C) received 3 doses of high, middle, and low D antigen (D Ag) of Sabin IPV at ages 2, 3, and 4 months, respectively. Infants in 2 control groups, group D and group E, received 3 doses of trivalent OPV and conventional IPV (cIPV), respectively, on the same schedule as that of groups A, B, and C. Serum samples were collected before and 30 days after the administration of the third dose. Results. In total, 500 infants were randomly assigned to 5 groups, and 449 infants completed the vaccine series. No serious adverse events were associated with vaccinations. After 3 doses, the seroconversion rates in groups A, B, C, D, and E were 100%, 97.8%, 96.6%, 100%, and 90.1%, respectively, for type 1 poliovirus; 97.7%, 95.7%, 78.7%, 100%, and 90.1%, respectively, for type 2; and 98.8%, 98.9%, 93.3%, 100%, and 97.8%, respectively, for type 3. Conclusions. Sabin IPV has good safety characteristics. The seroconversion rates for type 1 poliovirus (most appropriate concentration, 15 D Ag units [DU]), type 2 (32 DU), and type 3 (45 DU) Sabin IPV were similar to those of the OPV and cIPV control groups. Clinical Trials Registration. NCT01056705. Background. The production of Sabin inactivated poliovirus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine (OPV) era. We conducted a phase II, randomized, positive-controlled trial to assess the safety and immunogenicity of Sabin IPV. Methods. The test groups (A, B, and C) received 3 doses of high, middle, and low D antigen (D Ag) of Sabin IPV at ages 2, 3, and 4 months, respectively. Infants in 2 control groups, group D and group E, received 3 doses of trivalent OPV and conventional IPV (cIPV), respectively, on the same schedule as that of groups A, B, and C. Serum samples were collected before and 30 days after the administration of the third dose. Results. In total, 500 infants were randomly assigned to 5 groups, and 449 infants completed the vaccine series. No serious adverse events were associated with vaccinations. After 3 doses, the seroconversion rates in groups A, B, C, D, and E were 100%, 97.8%, 96.6%, 100%, and 90.1%, respectively, for type 1 poliovirus; 97.7%, 95.7%, 78.7%, 100%, and 90.1%, respectively, for type 2; and 98.8%, 98.9%, 93.3%, 100%, and 97.8%, respectively, for type 3. Conclusions. Sabin IPV has good safety characteristics. The seroconversion rates for type 1 poliovirus (most appropriate concentration, 15 D Ag units [DU]), type 2 (32 DU), and type 3 (45 DU) Sabin IPV were similar to those of the OPV and cIPV control groups. Clinical Trials Registration. NCT01056705. Background. The production of Sabin inactivated poliovirus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine (OPV) era. We conducted a phase II, randomized, positive-controlled trial to assess the safety and immunogenicity of Sabin IPV. Methods. The test groups (A, B, and C) received 3 doses of high, middle, and low D antigen (D Ag) of Sabin IPV at ages 2, 3, and 4 months, respectively. Infants in 2 control groups, group D and group E, received 3 doses of trivalent OPV and conventional IPV (cIPV), respectively, on the same schedule as that of groups A, B, and C. Serum samples were collected before and 30 days after the administration of the third dose. Results. In total, 500 infants were randomly assigned to 5 groups, and 449 infants completed the vaccine series. No serious adverse events were associated with vaccinations. After 3 doses, the seroconversion rates in groups A, B, C, D, and E were 100%, 97.8%, 96.6%, 100%, and 90.1%, respectively, for type 1 poliovirus; 97.7%, 95.7%, 78.7%, 100%, and 90.1%, respectively, for type 2; and 98.8%, 98.9%, 93.3%, 100%, and 97.8%, respectively, for type 3. Conclusions. Sabin IPV has good safety characteristics. The seroconversion rates for type 1 poliovirus (most appropriate concentration, 15 D Ag units [DU]), type 2 (32 DU), and type 3 (45 DU) Sabin IPV were similar to those of the OPV and cIPV control groups. The production of Sabin inactivated poliovirus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine (OPV) era. We conducted a phase II, randomized, positive-controlled trial to assess the safety and immunogenicity of Sabin IPV.BACKGROUNDThe production of Sabin inactivated poliovirus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine (OPV) era. We conducted a phase II, randomized, positive-controlled trial to assess the safety and immunogenicity of Sabin IPV.The test groups (A, B, and C) received 3 doses of high, middle, and low D antigen (D Ag) of Sabin IPV at ages 2, 3, and 4 months, respectively. Infants in 2 control groups, group D and group E, received 3 doses of trivalent OPV and conventional IPV (cIPV), respectively, on the same schedule as that of groups A, B, and C. Serum samples were collected before and 30 days after the administration of the third dose.METHODSThe test groups (A, B, and C) received 3 doses of high, middle, and low D antigen (D Ag) of Sabin IPV at ages 2, 3, and 4 months, respectively. Infants in 2 control groups, group D and group E, received 3 doses of trivalent OPV and conventional IPV (cIPV), respectively, on the same schedule as that of groups A, B, and C. Serum samples were collected before and 30 days after the administration of the third dose.In total, 500 infants were randomly assigned to 5 groups, and 449 infants completed the vaccine series. No serious adverse events were associated with vaccinations. After 3 doses, the seroconversion rates in groups A, B, C, D, and E were 100%, 97.8%, 96.6%, 100%, and 90.1%, respectively, for type 1 poliovirus; 97.7%, 95.7%, 78.7%, 100%, and 90.1%, respectively, for type 2; and 98.8%, 98.9%, 93.3%, 100%, and 97.8%, respectively, for type 3.RESULTSIn total, 500 infants were randomly assigned to 5 groups, and 449 infants completed the vaccine series. No serious adverse events were associated with vaccinations. After 3 doses, the seroconversion rates in groups A, B, C, D, and E were 100%, 97.8%, 96.6%, 100%, and 90.1%, respectively, for type 1 poliovirus; 97.7%, 95.7%, 78.7%, 100%, and 90.1%, respectively, for type 2; and 98.8%, 98.9%, 93.3%, 100%, and 97.8%, respectively, for type 3.Sabin IPV has good safety characteristics. The seroconversion rates for type 1 poliovirus (most appropriate concentration, 15 D Ag units [DU]), type 2 (32 DU), and type 3 (45 DU) Sabin IPV were similar to those of the OPV and cIPV control groups.CONCLUSIONSSabin IPV has good safety characteristics. The seroconversion rates for type 1 poliovirus (most appropriate concentration, 15 D Ag units [DU]), type 2 (32 DU), and type 3 (45 DU) Sabin IPV were similar to those of the OPV and cIPV control groups.NCT01056705.CLINICAL TRIALS REGISTRATIONNCT01056705. |
| Author | Li, Rongcheng Liao, Guoyang Li, Changgui Li, Yanping Jiang, Shude Sun, Mingbo Li, Qihan Chu, Jiayou |
| Author_xml | – sequence: 1 givenname: Guoyang surname: Liao fullname: Liao, Guoyang – sequence: 2 givenname: Rongcheng surname: Li fullname: Li, Rongcheng – sequence: 3 givenname: Changgui surname: Li fullname: Li, Changgui – sequence: 4 givenname: Mingbo surname: Sun fullname: Sun, Mingbo – sequence: 5 givenname: Yanping surname: Li fullname: Li, Yanping – sequence: 6 givenname: Jiayou surname: Chu fullname: Chu, Jiayou – sequence: 7 givenname: Shude surname: Jiang fullname: Jiang, Shude – sequence: 8 givenname: Qihan surname: Li fullname: Li, Qihan |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25877535$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22158682$$D View this record in MEDLINE/PubMed |
| BookMark | eNqF0U1rFDEcBvAgFbutHj0quYgeOjYvkzdvZWl1oWJxq9fhv5mMZplJtslMoX6Afm6z7FpBUE8J4ZcnL88ROggxOISeU_KWEsNPfehan0_XPinGH6EZFVxVUlJ-gGaEMFZRbcwhOsp5TQipuVRP0CFjVGip2QzdL6Fz4x2G0OLFMEwhfnPBW1-WYocXAezob2F0Lb6KvY-3Pk0ZfwVrfXD4I7QOX6Q44CWsfMDLMYEP-R0-w1ffITu8WJzgzyU6Dv6Ha09KRvYlz1XzGMYU-77kXicP_VP0uIM-u2f78Rh9uTi_nn-oLj-9X8zPLitbKzlWkhPDzIrK2hClCVFCMwotMNJpq7nRTijZSiI6IWRd5k5b2QqgQjHJgPFj9HqXu0nxZnJ5bAafret7CC5OuTGUSa5MbYp8809Z7sAkZVptQ1_u6bQaXNtskh8g3TW_frmAV3sA2ULfJQjW599OaKUEF8VVO2dTzDm57oFQ0mzbbnZtN7u2i-d_-FIcjH77ueD7v-7avyxOm_8e8GJH13mM6QHXtKZKGsF_ApeJxkw |
| CODEN | JIDIAQ |
| CitedBy_id | crossref_primary_10_1186_s12879_020_05348_1 crossref_primary_10_3390_vaccines10020254 crossref_primary_10_2222_jsv_62_57 crossref_primary_10_1016_j_vaccine_2014_11_015 crossref_primary_10_1016_j_vaccine_2015_10_091 crossref_primary_10_1016_j_vaccine_2020_05_081 crossref_primary_10_1080_21645515_2018_1526553 crossref_primary_10_1016_j_vaccine_2013_12_025 crossref_primary_10_1111_risa_12019 crossref_primary_10_1586_14760584_2015_1012503 crossref_primary_10_1016_j_biologicals_2016_08_005 crossref_primary_10_1016_j_vaccine_2021_02_073 crossref_primary_10_1111_tan_14575 crossref_primary_10_1080_21645515_2020_1745593 crossref_primary_10_1080_21645515_2020_1812315 crossref_primary_10_1093_infdis_jit155 crossref_primary_10_1016_j_vaccine_2015_03_076 crossref_primary_10_1016_j_eclinm_2023_102151 crossref_primary_10_1016_j_vaccine_2021_01_027 crossref_primary_10_1002_jmv_25289 crossref_primary_10_4155_ppa_12_70 crossref_primary_10_1080_21645515_2016_1214347 crossref_primary_10_1016_j_vaccine_2024_02_042 crossref_primary_10_1016_j_vaccine_2016_02_067 crossref_primary_10_1080_21645515_2019_1572408 crossref_primary_10_3390_vaccines12020217 crossref_primary_10_1016_j_vaccine_2013_09_021 crossref_primary_10_1056_NEJMoa1202541 crossref_primary_10_1016_j_vaccine_2018_09_023 crossref_primary_10_1016_j_vaccine_2018_09_068 crossref_primary_10_1093_infdis_jiw433 crossref_primary_10_1371_journal_pone_0083374 crossref_primary_10_1098_rstb_2012_0140 crossref_primary_10_1097_MD_0000000000007073 crossref_primary_10_1586_14760584_2014_864563 crossref_primary_10_1002_jmv_25298 crossref_primary_10_1080_21645515_2022_2044255 crossref_primary_10_1093_cid_cix110 crossref_primary_10_1016_j_xphs_2022_01_031 crossref_primary_10_1080_21645515_2017_1288769 crossref_primary_10_1016_j_biologicals_2012_12_004 crossref_primary_10_1080_21645515_2022_2041944 crossref_primary_10_1016_j_coi_2012_03_014 crossref_primary_10_1080_14760584_2017_1322514 crossref_primary_10_1016_S1473_3099_19_30738_8 crossref_primary_10_1016_j_trivac_2015_08_001 crossref_primary_10_1016_j_vaccine_2014_07_065 crossref_primary_10_1080_14760584_2021_1919091 crossref_primary_10_1080_21645515_2019_1709352 crossref_primary_10_4161_hv_32253 crossref_primary_10_1016_j_vaccine_2014_07_109 crossref_primary_10_1016_j_vaccine_2014_07_029 crossref_primary_10_1016_j_coviro_2013_05_007 crossref_primary_10_3389_fmicb_2021_757375 crossref_primary_10_1586_14760584_2015_1001750 crossref_primary_10_1016_j_vaccine_2018_11_020 crossref_primary_10_1080_21645515_2019_1572410 crossref_primary_10_1016_S0140_6736_12_61948_5 crossref_primary_10_1371_journal_ppat_1005483 crossref_primary_10_1016_j_biologicals_2022_01_005 crossref_primary_10_2217_fvl_2018_0079 |
| Cites_doi | 10.1016/j.biologicals.2006.02.010 10.1016/j.vaccine.2009.02.071 10.1016/j.biologicals.2006.02.011 10.1056/NEJMoa0910074 10.1016/0092-1157(86)90028-4 10.1086/499970 10.1016/S0264-410X(98)00409-5 10.1586/erv.11.51 |
| ContentType | Journal Article |
| Copyright | Copyright © 2012 Oxford University Press on behalf of the Infectious Diseases Society of America The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com 2011 2015 INIST-CNRS |
| Copyright_xml | – notice: Copyright © 2012 Oxford University Press on behalf of the Infectious Diseases Society of America – notice: The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com 2011 – notice: 2015 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 |
| DOI | 10.1093/infdis/jir723 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1537-6613 |
| EndPage | 243 |
| ExternalDocumentID | 22158682 25877535 10_1093_infdis_jir723 10.1093/infdis/jir723 41417695 |
| Genre | Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -DZ -~X ..I .2P .I3 .XZ .ZR 08P 0R~ 123 1KJ 1TH 29K 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAJQQ AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWTL ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACGFO ACGFS ACGOD ACHIC ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQVQM ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BTRTY BVRKM C45 CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DU5 D~K EBS ECGQY EE~ EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 MHKGH MJL ML0 N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TR2 W2D W8F WH7 X7H YAYTL YKOAZ YXANX ~91 .55 .GJ 3O- 41~ 6.Y AAPGJ AASNB AAWDT AAYOK ABSAR ABSMQ ACFRR ACMRT ACPQN ACZBC ADACV ADJQC ADRIX AEKPW AFHKK AFSHK AFXEN AGKRT AGMDO AI. APJGH AQDSO AQKUS AVNTJ BZKNY DOOOF EIHJH ESX G8K HQ3 HTVGU J5H JSODD M49 MBLQV MVM N4W NEJ O~Y P0- TMA VH1 X7M Y6R ZE2 ZGI ZKG ZXP AAYXX CITATION AAFWJ ABDPE ACVCV ADMTO AFFQV AFQQW AHGBF AJDVS IQODW OBFPC CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 |
| ID | FETCH-LOGICAL-c476t-630929b16490780075821ada20f8c8398e576d605f5564576e8c6d5a157262a23 |
| ISSN | 0022-1899 1537-6613 |
| IngestDate | Mon Sep 29 05:57:25 EDT 2025 Thu Oct 02 10:23:21 EDT 2025 Mon Jul 21 06:04:33 EDT 2025 Mon Jul 21 09:14:45 EDT 2025 Thu Apr 24 22:50:30 EDT 2025 Wed Oct 01 03:31:04 EDT 2025 Wed Aug 28 03:24:10 EDT 2024 Fri Jun 20 02:31:45 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Virus Infection Immunogenicity Picornaviridae Vaccine strain Phase II trial Enterovirus Poliovirus Inactivated strain |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c476t-630929b16490780075821ada20f8c8398e576d605f5564576e8c6d5a157262a23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 ObjectType-Undefined-3 |
| PMID | 22158682 |
| PQID | 1642612872 |
| PQPubID | 23462 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_912637949 proquest_miscellaneous_1642612872 pubmed_primary_22158682 pascalfrancis_primary_25877535 crossref_primary_10_1093_infdis_jir723 crossref_citationtrail_10_1093_infdis_jir723 oup_primary_10_1093_infdis_jir723 jstor_primary_41417695 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-01-15 |
| PublicationDateYYYYMMDD | 2012-01-15 |
| PublicationDate_xml | – month: 01 year: 2012 text: 2012-01-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: United States |
| PublicationTitle | The Journal of infectious diseases |
| PublicationTitleAlternate | J Infect Dis |
| PublicationYear | 2012 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | key 20170702150527_bib4 Simizu ( key 20170702150527_bib22) 2006; 34 Kersten ( key 20170702150527_bib18) 1999; 17 key 20170702150527_bib6 key 20170702150527_bib7 key 20170702150527_bib1 Hickling ( key 20170702150527_bib17) 2010 Ivanov ( key 20170702150527_bib24) 2006; 193 Verdijk ( key 20170702150527_bib20) 2011; 10 Doi ( key 20170702150527_bib21) 2001; 105 Kreeftenberg ( key 20170702150527_bib19) 2006; 34 key 20170702150527_bib11 key 20170702150527_bib12 Jiang ( key 20170702150527_bib16) 1986; 14 Long ( key 20170702150527_bib23) 1992; 5 key 20170702150527_bib13 key 20170702150527_bib14 Minor ( key 20170702150527_bib2) 2009; 27 key 20170702150527_bib15 Jenkins ( key 20170702150527_bib3) 2010; 362 key 20170702150527_bib8 ( key 20170702150527_bib5) 2009; 58 key 20170702150527_bib9 key 20170702150527_bib10 22158681 - J Infect Dis. 2012 Jan 15;205(2):169-71 |
| References_xml | – ident: key 20170702150527_bib6 – volume: 105 start-page: 163 year: 2001 ident: key 20170702150527_bib21 article-title: Progress with inactivated poliovirus vaccines derived from the Sabin strains publication-title: Dev Biol (Basel) – volume: 34 start-page: 151 year: 2006 ident: key 20170702150527_bib22 article-title: Development of inactivated poliovirus vaccine derived from Sabin strains publication-title: Biologicals doi: 10.1016/j.biologicals.2006.02.010 – volume: 27 start-page: 2649 year: 2009 ident: key 20170702150527_bib2 article-title: Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication publication-title: Vaccine doi: 10.1016/j.vaccine.2009.02.071 – year: 2010 ident: key 20170702150527_bib17 article-title: Improving the affordability of inactivated poliovirus vaccine (IPV) for use in low-and middle-income countries – volume: 34 start-page: 155 year: 2006 ident: key 20170702150527_bib19 article-title: Technology transfer to new developing country markets publication-title: Biologicals doi: 10.1016/j.biologicals.2006.02.011 – volume: 362 start-page: 2360 year: 2010 ident: key 20170702150527_bib3 article-title: Implications of a circulating vaccine-derived poliovirus in Nigeria publication-title: N Engl J Med doi: 10.1056/NEJMoa0910074 – volume: 14 start-page: 103 year: 1986 ident: key 20170702150527_bib16 article-title: Inactivation of poliovirus with beta-propiolactone publication-title: J Biol Stand doi: 10.1016/0092-1157(86)90028-4 – volume: 5 start-page: 55 year: 1992 ident: key 20170702150527_bib23 article-title: Comparison of inactivated poliovirus vaccine made from attenuated and wild strains publication-title: Chin J Biol – volume: 193 start-page: 598 year: 2006 ident: key 20170702150527_bib24 article-title: 25-dihydroxyvitamin D3 enhances immune responses to inactivated poliovirus vaccine in mice publication-title: J Infect Dis doi: 10.1086/499970 – ident: key 20170702150527_bib15 – volume: 17 start-page: 2059 year: 1999 ident: key 20170702150527_bib18 article-title: Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains publication-title: Vaccine doi: 10.1016/S0264-410X(98)00409-5 – ident: key 20170702150527_bib14 – ident: key 20170702150527_bib13 – ident: key 20170702150527_bib1 – ident: key 20170702150527_bib10 – volume: 58 start-page: 1002 year: 2009 ident: key 20170702150527_bib5 article-title: Update on vaccine-derived polioviruses—worldwide January 2008–June 2009 publication-title: MMWR Morb Mortal Wkly Rep – ident: key 20170702150527_bib11 – ident: key 20170702150527_bib12 – ident: key 20170702150527_bib8 – ident: key 20170702150527_bib9 – volume: 10 start-page: 635 year: 2011 ident: key 20170702150527_bib20 article-title: Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains publication-title: Expert Rev Vaccines doi: 10.1586/erv.11.51 – ident: key 20170702150527_bib7 – ident: key 20170702150527_bib4 – reference: 22158681 - J Infect Dis. 2012 Jan 15;205(2):169-71 |
| SSID | ssj0004367 |
| Score | 2.3340213 |
| Snippet | Background. The production of Sabin inactivated polio virus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine... Background. The production of Sabin inactivated poliovirus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine... The production of Sabin inactivated poliovirus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine (OPV) era.... Background. The production of Sabin inactivated poliovirus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine... |
| SourceID | proquest pubmed pascalfrancis crossref oup jstor |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 237 |
| SubjectTerms | Antibodies Antibodies, Viral - blood Biological and medical sciences Chi-Square Distribution Confidence Intervals Dosage Female Fundamental and applied biological sciences. Psychology Humans Immune response Inactivated poliovirus vaccine Infant Infectious diseases Lost to follow up Male Medical sciences Microbiology Miscellaneous Oral poliovirus vaccine Poliomyelitis Poliomyelitis - immunology Poliovirus Poliovirus - immunology Poliovirus Vaccine, Inactivated - administration & dosage Poliovirus Vaccine, Inactivated - adverse effects Poliovirus Vaccine, Inactivated - immunology Poliovirus Vaccine, Oral - administration & dosage Poliovirus Vaccine, Oral - adverse effects Poliovirus Vaccine, Oral - immunology Vaccination Virology Viruses |
| Title | Safety and Immunogenicity of Inactivated Poliovirus Vaccine Made From Sabin Strains: A Phase II, Randomized, Positive-Controlled Trial |
| URI | https://www.jstor.org/stable/41417695 https://www.ncbi.nlm.nih.gov/pubmed/22158682 https://www.proquest.com/docview/1642612872 https://www.proquest.com/docview/912637949 |
| Volume | 205 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1537-6613 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004367 issn: 0022-1899 databaseCode: KQ8 dateStart: 19970401 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1537-6613 dateEnd: 20241101 omitProxy: true ssIdentifier: ssj0004367 issn: 0022-1899 databaseCode: DIK dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1537-6613 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004367 issn: 0022-1899 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKEAgJIRgMymUyEuKly9bYsZ3whhBjRYyXbVLfIsdxStCaVF1bafsB_AR-L8eXNulYxeUlqhwnVvN9to_t852D0JtQF3GfUhGENC-CiCUkkEUoA6pIXwmm4jwx4uTjr_zoLPo8ZMNO52fLa2k-y_bV1Y26kv9BFcoAV6OS_QdkVy-FAvgN-MIVEIbrX2F8IgvjcWn3_43Oo4aapfJOFmVlNAsLaUxKk4qhXpTT-UVvIZU5S--NZa6duOREwurYiEak2Xu24ufJN5jceoOBAQAms7wel1duV9Q5eS104H3cz-HtNvNH28pt9GY-JIVz-ILW_XnQypD_Ukq7V_tpXl9KP4naYuf1XY2AU9eLrSBiNC-b8ywvAKhGWd3exbDuIIHTce7r5cgrAjAWaHtoJn3W4iBpD7QuVMxvE4ALjgVFuQnRcPi9nAqnZ27RYTK2fCBg7cTcpT66FnN7eesWuk1gtrApQYaN61BEufDxWqG9A9fagWvLRJf2T6-ZOs7bdSmjvD-RF9AHC5c8ZfPqxlo5pw_RAw8afu-49gh1dLWN7riEpZfb6O6xd8V4jH448mFgB14nH64L3CIfbsiHPfmwIR825MOWfNiT7x2W2FIPDwZ7uCHeHr6BdtjS7gk6O_x4-uEo8Ek9AhUJPgs47YNFnsEqPQHr1FisMQllLkm_iBVY67GGFXAOi-yCmUBHgutY8ZzJkAnCiSR0B21VdaWfIUxFWFCd5ZGKSJRwIbUwGxwsUUmYZHHRRXvL758qH_He_J3z1Hle0NQhlzrkuujtqvrEhXrZVHHHgrmqFYVRKHjCuug1oPunh3fXsF_VJiwWglHzkiUZUhjqzfmdrDR00RS-mQn4FwvSRXhDnSQknMIcm3TRU0ekpgFPy-cb77xA95q--RJtzaZz_Qps7lm2azvAL80-3Cc |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+immunogenicity+of+inactivated+poliovirus+vaccine+made+from+Sabin+strains%3A+a+phase+II%2C+randomized%2C+positive-controlled+trial&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Liao%2C+Guoyang&rft.au=Li%2C+Rongcheng&rft.au=Li%2C+Changgui&rft.au=Sun%2C+Mingbo&rft.date=2012-01-15&rft.eissn=1537-6613&rft.volume=205&rft.issue=2&rft.spage=237&rft_id=info:doi/10.1093%2Finfdis%2Fjir723&rft_id=info%3Apmid%2F22158682&rft.externalDocID=22158682 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |